How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?

被引:18
作者
Carta, Anna R.
Pinna, Annalisa
Morelli, Micaela
机构
[1] Univ Cagliari, Dept Toxicol, I-09124 Cagliari, Italy
[2] Univ Cagliari, Ctr Excellence Neurobiol Dependence, I-09124 Cagliari, Italy
[3] CNR, Inst Neurosci, Sect Cagliari, Cagliari, Italy
来源
BEHAVIOURAL PHARMACOLOGY | 2006年 / 17卷 / 5-6期
关键词
abnormal and involuntary movements; animal model; context; dopamine receptor; dyskinesia; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Parkinson's disease; primate; rat turning behaviour; 6-hydroxydopamine;
D O I
10.1097/00008877-200609000-00005
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
In spite of the current availability of several pharmacological therapies for the treatment of Parkinson's disease, side effects are invariably manifested during long-term treatment Dyskinesia, wearing-off and on-off are among the most disabling side effects produced by the dopamine precursor L-dihydroxyphenylalanine and, to a lesser degree, by other pharmacological treatments based on dopamine receptor agonism. Evaluation of the side effects, in particular dyskinesia, produced by antiparkinsonian drug treatments, therefore represents a critical issue in drug validation prior to a clinical trial. Moreover, a reliable model of dyskinesia is a fundamental requirement for the study of the as yet unknown mechanisms at the basis of this severely disabling side effect. The present review aims to provide a critical evaluation of the validity, reliability and utility of animal models of dyskinesia. In the first part of this review, we present a brief overview of the different models of Parkinson's disease focusing on those utilized for the evaluation of dyskinetic movements, then proceed to critically examine the turning behaviour model in an attempt to assess the way in which it has influenced the evaluation of drugs utilized in the treatment of Parkinson's disease. Subsequently, the various models of dyskinesia are reviewed and conclusions are drawn as to how the environment in which experiments are performed can influence the behaviour observed.
引用
收藏
页码:393 / 402
页数:10
相关论文
共 95 条
[41]   Avoidance of dyskinesia - Preclinical evidence for continuous dopaminergic stimulation [J].
Jenner, P .
NEUROLOGY, 2004, 62 (01) :S47-S55
[42]   A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease [J].
Johnston, TH ;
Lee, J ;
Gomez-Ramirez, J ;
Fox, SH ;
Brotchie, JM .
EXPERIMENTAL NEUROLOGY, 2005, 191 (02) :243-250
[43]   CONTINUOUS AND INTERMITTENT LEVODOPA DIFFERENTIALLY AFFECT BASAL GANGLIA FUNCTION [J].
JUNCOS, JL ;
ENGBER, TM ;
RAISMAN, R ;
SUSEL, Z ;
THIBAUT, F ;
PLOSKA, A ;
AGID, Y ;
CHASE, TN .
ANNALS OF NEUROLOGY, 1989, 25 (05) :473-478
[44]   Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? [J].
Lane, EL ;
Cheetham, SC ;
Jenner, P .
EXPERIMENTAL NEUROLOGY, 2006, 197 (02) :284-290
[45]   CHRONIC PARKINSONISM IN HUMANS DUE TO A PRODUCT OF MEPERIDINE-ANALOG SYNTHESIS [J].
LANGSTON, JW ;
BALLARD, P ;
TETRUD, JW ;
IRWIN, I .
SCIENCE, 1983, 219 (4587) :979-980
[46]   EFFECTS OF NIGROSTRIATAL DENERVATION AND L-DOPA THERAPY ON THE GABAERGIC NEURONS OF THE STRIATUM IN MPTP-TREATED MONKEYS AND PARKINSONS-DISEASE - AN IN-SITU HYBRIDIZATION STUDY OF GAD(67) MESSENGER-RNA [J].
LEVY, R ;
HERRERO, MT ;
RUBERG, M ;
VILLARES, J ;
FAUCHEUX, B ;
GURIDI, J ;
GUILLEN, J ;
LUQUIN, MR ;
JAVOYAGID, F ;
OBESO, JA ;
AGID, Y ;
HIRSCH, EC .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1995, 7 (06) :1199-1209
[47]  
Lozano AM, 2000, ANN NEUROL, V47, pS141
[48]   Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease [J].
Lundblad, M ;
Andersson, M ;
Winkler, C ;
Kirik, D ;
Wierup, N ;
Cenci, MA .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2002, 15 (01) :120-132
[49]   Pharmacological validation of a mouse model of L-DOPA-induced dyskinesia [J].
Lundblad, N ;
Usiello, A ;
Carta, M ;
Hakansson, K ;
Fisone, G ;
Cenci, MA .
EXPERIMENTAL NEUROLOGY, 2005, 194 (01) :66-75
[50]   Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus) [J].
Maratos, EC ;
Jackson, MJ ;
Pearce, RKB ;
Cannizzaro, C ;
Jenner, P .
EXPERIMENTAL NEUROLOGY, 2003, 179 (01) :90-102